Mallinckrodt Public Limited Company ROE 2012-2018 | MNK

Current and historical return on equity (ROE) values for Mallinckrodt Public Limited Company (MNK) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Mallinckrodt Public Limited Company ROE for the three months ending September 30, 2018 was 9.60%.
Mallinckrodt Public Limited Company ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2018-09-30 $1.72B $6.60B 26.41%
2018-06-30 $1.67B $6.47B 27.20%
2018-03-31 $1.72B $6.46B 29.63%
2017-12-31 $2.14B $6.52B 39.09%
2017-09-30 $0.53B $5.11B 10.36%
2017-06-30 $0.58B $5.10B 15.19%
2017-03-31 $0.71B $5.11B 18.63%
2016-12-31 $0.43B $4.98B 11.30%
2016-09-30 $0.64B $0.00B 16.59%
2016-06-30 $0.53B $5.21B 10.15%
2016-03-31 $0.39B $5.10B 7.41%
2015-12-31 $0.37B $5.19B 7.01%
2015-09-30 $0.25B $5.31B 4.79%
2015-06-30 $-0.10B $5.30B -1.99%
2015-03-31 $-0.18B $5.19B -4.45%
2014-12-31 $-0.27B $5.07B -8.54%
2014-09-30 $-0.32B $4.96B -14.24%
2014-06-30 $0.07B $1.33B 5.20%
2014-03-31 $0.06B $1.34B 5.06%
2013-12-31 $0.09B $1.31B 9.24%
2013-09-30 $0.06B $1.26B 9.78%
2013-06-30 $0.05B $1.16B 6.69%
2013-03-31 $0.11B $0.00B 23.68%
2012-12-31 $0.08B $0.00B 16.49%
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $2.589B $3.222B
Mallinckrodt Plc. is engaged in pharmaceuticals business. It develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. The company's Specialty Pharmaceuticals segment includes branded and generic drugs and Medical Imaging segment includes contrast media and nuclear imaging agents. Mallinckrodt Plc. is based in Dublin, Ireland.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $54.860B 9.42
Teva Pharmaceutical Industries (TEVA) Israel $23.927B 7.33
Mylan (MYL) United Kingdom $18.439B 7.59
Bausch Health Cos (BHC) Canada $9.314B 6.74
Dr Reddy's Laboratories (RDY) India $5.645B 22.54
Supernus Pharmaceuticals (SUPN) United States $2.357B 22.33
Amphastar Pharmaceuticals (AMPH) United States $0.978B 106.05
Akorn (AKRX) United States $0.853B 0.00
Homology Medicines (FIXX) United States $0.748B 0.00
Assembly Biosciences (ASMB) United States $0.570B 0.00
CymaBay Therapeutics (CBAY) United States $0.536B 0.00
Corium (CORI) United States $0.458B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.451B 0.00
Voyager Therapeutics (VYGR) United States $0.384B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.315B 0.00
Teligent (TLGT) United States $0.170B 0.00
Sol-Gel Technologies (SLGL) Israel $0.135B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.095B 0.00
Aevi Genomic Medicine (GNMX) United States $0.076B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.053B 0.00
Evoke Pharma (EVOK) United States $0.046B 0.00
Acasti Pharma (ACST) Canada $0.042B 0.00
Agile Therapeutics (AGRX) United States $0.032B 0.00
China Pharma Holdings (CPHI) China $0.016B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.008B 0.00